26-05-2025
Lupin inks licensing deal to supply biosimilar ranibizumab in Latin America
Drug maker
Lupin
on Monday said it has entered into a licence and supply agreement with
SteinCares
for commercialisation of
biosimilar ranibizumab
across
Latin America
, excluding Mexico and Argentina. Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialisation of Ranibizumab in Latin America, while
Lupin
will be responsible for manufacturing the same, the Mumbai-based drug maker said in a statement.
Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A).
Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD),
Macular Edema
Following Retinal Vein Occlusion (RVO),
Diabetic Macular Edema
(DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Free P2,000 GCash eGift
UnionBank Credit Card
Apply Now
Undo
Also Read:
Lupin partners with Honeywell for usage of propellant for inhalers
"Our intent is to transform the landscape of
retinal care
in Latin America, ensuring access to advanced therapies that improve the quality of life of patients," Lupin President
Biotechnology
Cyrus Karkaria said.
Live Events
Shares of Lupin were trading 0.32% down at ₹1,972.80 apiece on BSE.
